The addition of antibody-drug conjugate (ADC) therapies to the treatment armamentarium for endocrine-refractory, HR-positive, HER2-negative metastatic breast cancer has greatly improved outcomes for patients in this setting. However, selecting the appropriate ADC and determining the optimal sequencing of these therapies may be challenging. In this activity, expert faculty in the field of breast cancer review the clinical burden related to endocrine-refractory disease, the role of ADCs in this setting, and best practices for the sequencing of these agents.
=Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
Accurate Staging and Determining Resectability in NSCLC
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
ATTR-CM Management: Pearls From Recent Clinical Trials and Tailoring Therapy
Are Two Pathways Better Than One? Experts Discuss the Role of Ang-2/VEGF-A Inhibition in Retinal Vascular Disease
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
The Role of Immunotherapy in the Treatment of Recurrent or Metastatic HNSCC: The Evidence
Current and Emerging Biomarkers of Response to Immunotherapeutic Regimens
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video